WINTON GROUP Ltd Cuts Stock Position in Globus Medical, Inc. $GMED

WINTON GROUP Ltd lessened its stake in shares of Globus Medical, Inc. (NYSE:GMED) by 80.8% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,600 shares of the medical device company’s stock after selling 69,834 shares during the period. WINTON GROUP Ltd’s holdings in Globus Medical were worth $951,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Russell Investments Group Ltd. grew its stake in shares of Globus Medical by 55.1% in the third quarter. Russell Investments Group Ltd. now owns 21,881 shares of the medical device company’s stock worth $1,253,000 after acquiring an additional 7,773 shares during the last quarter. Parallel Advisors LLC raised its position in shares of Globus Medical by 45.1% in the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after purchasing an additional 173 shares during the last quarter. Riggs Asset Managment Co. Inc. purchased a new position in shares of Globus Medical in the 3rd quarter worth about $211,000. Grantham Mayo Van Otterloo & Co. LLC boosted its stake in Globus Medical by 0.9% in the 3rd quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 728,438 shares of the medical device company’s stock worth $41,718,000 after purchasing an additional 6,657 shares in the last quarter. Finally, First Trust Advisors LP boosted its stake in Globus Medical by 21.5% in the 3rd quarter. First Trust Advisors LP now owns 151,754 shares of the medical device company’s stock worth $8,691,000 after purchasing an additional 26,821 shares in the last quarter. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Wall Street Analyst Weigh In

GMED has been the subject of a number of analyst reports. Canaccord Genuity Group raised their price objective on shares of Globus Medical from $105.00 to $112.00 and gave the company a “buy” rating in a research note on Friday, January 9th. BTIG Research reiterated a “neutral” rating on shares of Globus Medical in a research note on Tuesday, December 30th. TD Cowen upgraded shares of Globus Medical to a “strong-buy” rating in a report on Tuesday, January 27th. Wells Fargo & Company raised their price target on shares of Globus Medical from $98.00 to $104.00 and gave the company an “overweight” rating in a research report on Thursday, February 26th. Finally, Citigroup restated a “market perform” rating on shares of Globus Medical in a report on Thursday, January 8th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, Globus Medical currently has a consensus rating of “Moderate Buy” and an average target price of $104.36.

Globus Medical Stock Up 1.7%

GMED traded up $1.47 during midday trading on Friday, hitting $85.98. 181,051 shares of the company traded hands, compared to its average volume of 1,321,115. The company’s 50-day moving average is $90.76 and its 200 day moving average is $78.10. The firm has a market capitalization of $11.63 billion, a PE ratio of 21.83, a price-to-earnings-growth ratio of 2.04 and a beta of 1.05. Globus Medical, Inc. has a 52 week low of $51.79 and a 52 week high of $101.40.

Globus Medical (NYSE:GMED) last announced its quarterly earnings results on Tuesday, February 24th. The medical device company reported $1.28 EPS for the quarter, topping analysts’ consensus estimates of $1.06 by $0.22. Globus Medical had a net margin of 18.30% and a return on equity of 12.57%. The firm had revenue of $826.42 million during the quarter, compared to analyst estimates of $803.29 million. During the same period in the previous year, the business posted $0.84 earnings per share. The business’s revenue for the quarter was up 25.7% on a year-over-year basis. On average, sell-side analysts predict that Globus Medical, Inc. will post 3.44 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Globus Medical news, EVP Kelly Huller sold 20,000 shares of Globus Medical stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $94.50, for a total value of $1,890,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Kyle Kline sold 3,594 shares of the business’s stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $101.10, for a total transaction of $363,353.40. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 35,594 shares of company stock worth $3,332,253. 18.51% of the stock is owned by insiders.

More Globus Medical News

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Zacks Research materially raised EPS forecasts across quarters and years (Q4 2026, Q1–Q3 2027, FY2026 and FY2027), including lifting FY2027 to ~$4.66 and several quarterly beats vs. prior Zacks views; Zacks carries a “Strong‑Buy” on GMED — this increases earnings visibility and underpins buy‑side interest. Zacks / MarketBeat Coverage
• Positive Sentiment: Brokerage consensus remains favorable: AmericanBankingNews reports an average rating of “Moderate Buy” from covering brokerages, reinforcing demand from institutional investors. Globus Medical Given Average Rating of “Moderate Buy” by Brokerages

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.